Compare GBTG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBTG | CELC |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2020 | 2017 |
| Metric | GBTG | CELC |
|---|---|---|
| Price | $5.80 | $119.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $8.92 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.1M | 669.5K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 173.33 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $2,718,000,000.00 | N/A |
| Revenue This Year | $21.78 | N/A |
| Revenue Next Year | $4.29 | $720.19 |
| P/E Ratio | $26.34 | ★ N/A |
| Revenue Growth | ★ 12.17 | N/A |
| 52 Week Low | $4.96 | $9.64 |
| 52 Week High | $8.64 | $129.09 |
| Indicator | GBTG | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 51.74 |
| Support Level | $5.28 | $99.38 |
| Resistance Level | $5.88 | N/A |
| Average True Range (ATR) | 0.19 | 6.84 |
| MACD | -0.01 | -0.51 |
| Stochastic Oscillator | 43.03 | 58.91 |
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.